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Objective:  To  investigate  the  toxicological  effects  of cleistanthin  A  and  cleistanthin  B using
sub-chronic  toxicity  testing  in rodents.
Method: Cleistanthins  A  and  B  were  isolated  from  the  leaves  of Cleistanthus  collinus.  Both
the compounds  were  administered  orally  for 90 days  at the  concentration  of 12.5, 25
and  50  mg/kg,  and  the effects  on  blood  pressure,  biochemical  parameters  and  histology
were  assessed.  The  dose  for sub-chronic  toxicology  was determined  by ﬁxed  dose method
according to OECD  guidelines.
Result: Sub-chronic  toxicity  study  of  cleistanthins  A  and B  spanning  over  90 days  at  the  dose
levels of  12.5, 25  and  50 mg/kg  (once  daily, per oral)  revealed  a signiﬁcant  dose  dependant
toxic  effect  in lungs.  The  compounds  did  not  have  any  effect  on  the  growth  of the  rats.  The
food and  water  intake  of  the  animals  were  also  not  affected  by both  cleistanthins  A  and
B.  Both  the  compounds  did  not  have  any  signiﬁcant  effect  on  liver  and renal  markers.  The
histopathological  analysis  of  both  cleistanthins  A  and  B showed  dose  dependent  morpho-
logical  changes  in  the  brain,  heart,  lung,  liver  and  kidney.  When  compared  to cleistanthin
A,  cleistanthin  B had  more  toxic  effect  in  Wistar  rats. Both  the  compounds  have  produced  a
dose dependent  increase  of corpora  amylacea  in  brain  and  induced  acute  tubular  necrosis
in kidneys.  In addition,  cleistanthin  B caused  spotty  necrosis  of  liver  in  higher  doses.
Conclusion: The  present  study  concludes  that both  cleistanthin  A and  cleistanthin  B  exert
severe toxic  effects  on  lungs,  brain,  liver,  heart and  kidneys.  They  do  not  cause  any  signiﬁcant
pathological  change  in  the  reproductive  system;  neither  do they  induce  neurodegenerative
changes  in brain.  When  compared  to cleistanthin  A, cleistanthin  B is more  toxic  in rats.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe CC  B
1. IntroductionCleistanthin A and cleistanthin B are toxic constituents
present in the leaves of Cleistanthus collinus. The plant is
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most commonly used as a suicidal poison in the Southeast
Asian countries [1]. The mortality rate of C. collinus leaf
poisoning is around 20–60%. In the 1970s a series of
phytoconstituents was isolated from the leaves of C.
collinus and it includes eargic acid, diphyllin, collinusin,
cleistanthin A and cleistanthin B [2]. Later, it was reported
that  the diphyllin glycoside includes cleistanthins A and
B  and they are responsible for the C. collinus poisoning
[3] which causes severe toxic effects on the cardiac and
is is an open access article under the CC BY-NC-ND license
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he respiratory systems in patients. The poisonous effect
f  C. collinus was observed after 48–72 h of administra-
ion. Globally plant poisoning is not common, but it is
ontributing a signiﬁcant percentage to mortality in rural
ndia.  Young women in rural Indian subcontinent use C.
ollinus  poisoning as a method of deliberate self-harm
4]. According to literature, the C. collinus plant contains
ighly toxic lignan glycosides such as cleistanthins A and
 which were reported to inhibit a speciﬁc thio-dependent
nzyme [5]. Apart from cleistanthin A and cleistanthin
, the C. collinus leaves have more than 25 compounds
6]. The major constituents of the genus Cleistanthus are
rylnaphthalide lignan glycosides which are insoluble in
ater.  Arylnaphthalide lignan includes diphyllin, colli-
usin,  cleistanthin, taiwanin and other related compounds.
rylnaphthalide lignin is commonly present in Cleistanthus
atulus, Haplophyllum bucharicum, and Phyllanthus tox-
diifolius  and some of these plants are used for medicinal
urpose [7]. The mechanism of toxic effects of the plant
eaves  or its phytoconstituents such as cleistanthins A and
 remains unknown. Further these compounds have been
eported  to exert anticancer activity in vitro and in vivo
nd  may  have the potential to become lead compounds
8–10]. Hence the present study was planned to determine
he toxicological proﬁle of cleistanthins A and B and a
ub-chronic toxicity study of both the compounds was
lanned for the duration of 90 days.
. Method
.1. Animals
The study was approved by the Institute Animal Ethics
ommittee, and all experiments were carried out as per the
uidelines  of the Committee for the Purpose of Control and
upervision on Experiments on Animals (CPCSEA), India in
he  Department of Pharmacology, JIPMER, Pondicherry.
Healthy, adult, inbred strain of Wistar rats of both sexes
120  ± 10 g), Wistar female rats (150 ± 10 g) and Swiss
lbino female mice (25 ± 3 g) were obtained from the cen-
ral  animal house at JIPMER, Pondicherry. The Wistar rats
ere  used for the chronic toxicological studies and Swiss
lbino  mice were used for the single oral dose toxicity
tudies. The rodents were housed at 25 ± 2 ◦C and 55–65%
umidity in a 12:12 ± 1 h light-and-dark cycle. The animals
ere  fed with standard rat pellets (VRK Nutritional Solu-
ion,  Sangli, Maharastra) and water ad libitum.
.2. Isolation of cleistanthin A and cleistanthin B
The leaves of C. collinus (Roxb.) (Family: Euphorbiaceae)
ere collected in Sedrapet village of Puducherry, Union
ertiary of Pondicherry. The plant was identiﬁed and certi-
ed  (BSI/SC/5/23/08–09/Tech.241) by the Botanical Survey
f  India, Southern Circle, Coimbatore. Cleistanthins A and
 were isolated from the leaves using chromatographic
echniques, and the structure of each compound was con-
rmed  spectroscopically. Air-dried leaves of the plant were
owdered  and defatted with n-hexane and subsequently
xtracted with acetone. The acetone extract was dissolved
n  benzene and passed through a neutral alumina column.eports 1 (2014) 596–611 597
The  fractions were collected with benzene, benzene:ethyl
acetate (4:1), benzene:ethyl acetate (1:1) and methanol.
The fractions were subjected to thin layer chromatog-
raphy and spectroscopic analysis. Cleistanthins A and B
were  obtained from the benzene:ethyl acetate (1:1) and
methanol fractions, respectively [11].
2.2.1. Single oral dose toxicity
The  single oral dose toxicity was performed to deter-
mine the dose for toxicity testing. The ﬁxed dose method
was  adopted for the study. The mice (25 ± 3 g) were
then randomly divided into different groups; each group
consisted of three mice. Both cleistanthins A and B were
administered at the dose levels of 3, 30, 300, and 600,
1200 mg/kg by gavage. The study started with adminis-
tration of the compounds (3 mg/kg) and the animals were
observed for 24 h continually for mortality. The animals
which were alive were observed for next 14 days. After
completion of the observation period, the next set of ani-
mals  was  administered with next dose level and observed
[12].
2.3.  Repeated dose toxicological evaluation of
cleistanthin A and cleistanthin B
Repeated dose toxicological evaluation of cleistanthins
A and B was  performed to determine the maximum tol-
erable  dose for toxicity studies. Inbred strain of albino
Wistar rats of female gender weighing 150 ± 10 g used for
the  experiment. Six animals per group were used for the
repeated dose toxicity testing which was  carried out for 30
days  with doses of 50, 100, 200 and 400 mg/kg to deter-
mine the maximum tolerable dose. The study was initiated
with  a control group and a test group receiving a high
dose  i.e., 400 mg/kg of cleistanthin A or B. Since the mor-
tality  was  high, the evaluation dose was  slashed to 200
and  100 mg/kg. Cleistanthins A and B (100 and 200 mg/kg
respectively) induced mortality after 3 weeks and hence
the  repeated dose toxicity testing was carried out with
50  mg/kg dose level. During the study period, the organs
of  animals which died due to cleistanthins A and B were
collected and preserved in 10% v/v neutral formalin for
histopathological evaluation.
2.4.  Dose optimization
Based  on the dose determination study results, the
<1/10 of the toxic dose was  selected for sub-chronic toxic-
ity  testing. As per OECD guidelines, the maximum tolerable
dose  (MTD) was  optimized and used for the sub-chronic
toxicological evaluation of cleistanthins A and B [13,14].
The  repeated dose toxicological study was  started with
doses  of 50, 100, 200 and 400 mg/kg, and observed for phys-
iological  and behavioural changes and mortality in rats. At
the  end of the ﬁrst month, 100, 200 and 400 mg/kg cleistan-
thins  A and B administered groups showed a high rate of
mortality and behavioural alterations. The maximum tol-
erable  dose was  determined to be 50 mg/kg. Based on MTD,
three  doses viz. 12.5, 25 and 50 mg/kg were selected for the
sub-chronic toxicity testing.
icology R598 S. Parasuraman et al. / Tox
2.5. Sub-chronic toxicological evaluation of cleistanthin
A and cleistanthin B
Inbred  strain of albino Wistar rats of both sexes weigh-
ing 120 ± 10 g was used for the experiment. The animals
were divided into seven groups and each group comprised
of  six male and six female Wistar rats.
Group-I: Control
Group-II: Cleistanthin A 12.5 mg/kg
Group-III: Cleistanthin A 25 mg/kg
Group-IV:  Cleistanthin A 50 mg/kg
Group-V: Cleistanthin B 12.5 mg/kg
Group-VI: Cleistanthin B 25 mg/kg
Group-VII:  Cleistanthin B 50 mg/kg
Animals were selected and allowed to adapt for the
laboratory condition for a week and 0.5 ml  of blood was
collected from all animals for biochemical evaluation.
The animals which had normal biochemical proﬁles were
included in the study and divided randomly into experi-
mental groups. The experimental animals were observed
for  normal biological and physical functions for a week.
During that time the animal blood pressure was recorded
using a non-invasive procedure (Non-invasive blood pres-
sure  (NIBP) system, IITC Inc., USA).
The compounds were administered once daily as oral
suspension in the morning (between 7.00 am and 9.00 am)
by  gavage. The doses of the compounds were adjusted
to the body weight every week after the measurement
of weekly body weight. During the experimental period,
animals were fed with standard palatable diet and water
ad  libitum. Weekly body weight variations were calcu-
lated  for all the experimental animals. The variations in
blood  pressure were measured bimonthly and blood was
collected  every 30 days intervals and subjected to bio-
chemical evaluation. Before termination of the study, the
last  blood sample was collected from all groups of ani-
mals  for biochemical estimation and comet assay. Finally
the  experiential animals were euthanized by cervical
dislocation and the organs were collected and relative
weight was measured. A part of the brain, lung, heart,
stomach, kidney and bone marrow were preserved in
10%  v/v neutral formalin for histopathological examination
[15].
2.6.  Biochemical estimation
One  ml  of blood sample was collected in sodium EDTA
(1%  sodium EDTA in normal saline) containing sample col-
lection  tube. The blood sample was collected through the
retro  orbital sinus. Collected blood sample was centrifuged
at  3000 rpm for 20 min. The plasma was separated and
immediately processed for biochemical estimations.
The plasma sample was subjected to analysis of bio-
chemical parameters such as random blood glucose, urea,
creatinine, aspartate aminotransferase (AST/SGOT), ala-
nine  amino transferase (ALT/SGPT), alkaline phosphatase
(ALP), total protein, albumin and creatinine kinase–MB
(CK-MB) using commercial kits and an auto analyser
(Olympus AU 400, Japan).eports 1 (2014) 596–611
2.7.  Measurement of non-invasive blood pressure (NIBP)
The  NIBP was  performed with a tail-cuff apparatus (3
measurements per rat) with the use of non-invasive blood
pressure monitoring device through BP-MONWIN software
(NIBP  system, IITC, USA). The blood pressure was recorded
between 10–12 am and 3–5 pm of the day. The animals
were acclimatized to stay comfortably in a rat restrainer.
After restraining the animal the tail was  connected to a
photosensitive detector which in turn was  connected to a
pressure  unit and a pressure cuff. After recording the blood
pressure, the animal was  relieved from the restrainer. After
10/15  min, the experimental procedure was repeated for
constancy [16,17].
2.8.  Blood sample collection for comet assay
One ml  of the blood was  collected in a heparinized tube
through the retro orbital sinus for analysis of percentage of
DNA  damage using comet assay [18].
2.9. Relative organ weight analysis
At the end of the study, experimental animals from all
the  groups were sacriﬁced by cervical dislocation proce-
dure.  The abdomen was cut open and organs such as brain,
heart,  lung, stomach, liver, kidney, testes in male rats and
uterus  in female rats were dissected. The removed organs
were  washed with normal saline, dried with ﬁlter paper
and  weighed [19].
Relative  organ weight = Weight of the organ(g)
Weight of the body(g)
×  100
2.10. Comet assay
The  lymphocytes from the blood sample were isolated
using lymphocyte separation media (Histopaque 1077;
Sigma, USA) and diluted with phosphate buffer saline
(PBS). The diluted lymphocytes were mixed with low melt-
ing  point agarose and the sandwich was  prepared using
normal agarose on glass microscopic slide and coverslip.
The lymphocytes-agarose sandwich was  preserved at 10 ◦C
for  15 min  to complete solidiﬁcation. The coverslip of
lymphocytes-agarose sandwich preparation was removed
and  placed in horizontal electrophoresis unit and allowed
for  DNA unwinding for 30 min  after that the electrophore-
sis was run for 30 min  at 10 V current. Then the slide
was  washed thrice with Tris buffer. The washed slide was
allowed  to overnight drying at room temperature.
Next day the slides were ﬁxed with freshly prepared
ﬁxating solution (trichloroacetic acid, zing sulphate and
glycerol  in water) for 10 min. After 10 min the slide was
removed from ﬁxating solution and washed with distilled
water  (three times) and allowed for drying. The dried slide
was  stained using silver, sodium carbonate in water – solu-
tion  A; ammonium nitrate, silver nitrate and silicotungstic
acid in water – solution B; Solutions A and B in the ratio
of  1:2 were used as silver staining solutions and then the
slide  was  transferred to a tray containing stopping solu-
tion  (glacial acetic acid). Finally the slide was  washed again
icology Reports 1 (2014) 596–611 599
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ith distilled water and allowed to dry completely in an
nclined  position at room temperature. The dried slides
ere  examined under bright-ﬁeld light microscope and
aptured  using CCD camera [18].
.11. Histopathological analysis
Part of the brain, heart, lung, liver and kidney were
xcised quickly and ﬁxed in 10% v/v buffered neutral for-
alin.  The parafﬁn blocks were prepared and the 5–10 m
hick  sections were prepared, stained with haematoxylin
nd eosin and mounted in neutral DPX medium. The histo-
ogical  slides were examined under light microscope [20].
.12.  Statistics
All  the data presented are mean ± SEM. One-way anal-
sis  of variance (ANOVA) followed by Bonferroni test for
lood  pressure, and two-way repeated measures ANOVA
ollowed by Bonferroni test for biochemical parameters
ere used to ﬁnd out the statistically signiﬁcant difference
etween groups. P values <0.05 was considered signiﬁcant.
.  Results and discussion
The  single oral dose administration of cleistanthins A
nd  B up to 800 mg/kg did not lead to mortality in mice.
oth  cleistanthin A and cleistanthin B exhibited mortality
t  1200 and 1000 mg/kg respectively. From the results of
he  repeated dose toxicity study, the maximum tolerable
ose (MTD) for cleistanthins A and B was calculated to be
0  mg/kg.
Fixed  single oral dose toxicity determination of cleis-
anthin A and cleistanthin B in mice showed Straub tail
henomenon. But such an effect was not observed in
ub-chronic toxicological study on rats. Both single and
hronic  administration of cleistanthin A and cleistanthin B
n  rodents do not have any effect on growth (Figs. 1 and 2).
he  food intake and the water intake of the animals were
lso  not affected by cleistanthins A and B. Single oral dose
oxicity  studies were carried out using mice because of
heir  high basal metabolic rate (BMR) and hence their tol-
rance  to higher dose (per kg body weight). This reduced
he  mortality and helped us ﬁnd out the safe dose with the
ncreasing doses of cleistanthins A and B. The sub-chronic
oxicity studies were conducted using rats considering
heir longer lifespan.
Sub-chronic toxicity study of cleistanthin A and cleis-
anthin B spanning over 90 days at the dose levels of 12.5,
5  and 50 mg/kg (single dose, oral toxicity testing) revealed
 signiﬁcant dose dependant toxic effect in lungs. The effect
percentage change and area under curve [AUC]) of cleis-
anthins A and B on diastolic blood pressure and mean
lood pressure is presented in Tables 1 and 2. Both cleis-
anthins A and B did not show any signiﬁcant change in
ystolic,  diastolic and mean blood pressures.
Both cleistanthins A and B signiﬁcantly altered the
iochemical parameters (Tables 3–6) and the mortality
bserved at the end of the study, in cleistanthins A and
 groups is given in Tables 7 and 8). In both the groups,
ortality is more with the highest dose used (400 mg/kg). Ta
b
le
 
1
Ef
fe
ct
 
of
 
cl
ei
s
G
ro
u
p
 
C
on
tr
ol
 
C
le
is
ta
n
th
i
C
le
is
ta
n
th
i
C
le
is
ta
n
th
i
C
le
is
ta
n
th
i
C
le
is
ta
n
th
i
C
le
is
ta
n
th
i
Th
e 
va
lu
es
 
ar
600 S. Parasuraman et al. / Toxicology Reports 1 (2014) 596–611
nd B onFig. 1. Effect of cleistanthins A a
Histopathology of the lung also showed severe interstitial
pneumonitis and crystalline deposition in the cleistanthin
A  (50 mg/kg) administered group (Table 9) and extensive
destruction of lung parenchyma, crystalline deposition,
severe interstitial pneumonitis, necrosis and pulmonary
haemorrhage in the cleistanthin B (50 mg/kg) administered
group (Table 10). The results of DNA comet assay which are
presented  in Table 11 clearly indicate the toxic effects of the
compounds on the DNA.
The overall blood pressure throughout the course has
not  changed signiﬁcantly as evident from the AUC of sys-
tolic,  diastolic and mean blood pressures. This is true for
both  the sexes. The change in blood pressure between pre-
study  and the 90th day also did not change. Though in
male  rats the %change appears to be more in cleistanthin
groups the difference could not achieve statistical signif-
icance  probably due to the small sample size. Heart rate
varied  so much within the groups and hence the statistical
Fig. 2. Effect of cleistanthins A and B on g growth of the male Wistar rats.
signiﬁcance was  not determined (only the AUC for heart
rate  is presented).
We  expected a gradual fall in blood pressure when cli-
estanthins were administered for a long time in our study
based  on the results from our earlier study but this did not
happen  [21]. Though the blood pressure seemed to have
fallen,  the change is not statistically signiﬁcant probably
due to the small sample size. Further our earlier study was
invasive  with drug being administered intravenously. The
dose  used in the acute study was much higher and it pro-
duced  a discernible reduction in blood pressure. Since the
dose  used in the current study of sub-chronic toxicity is
low,  the blood pressure did not fall much.
In male animals cleistanthin A showed a signiﬁcant
increase in the absolute organ weight of kidney and testis
at  the dose level of 12.5 mg/kg. This effect was not shared
by  cleistanthin B. But cleistanthin B showed an increase
in  the absolute organ weight of lung, kidney, liver and
rowth of the female Wistar rats.
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Table 2
Effect of cleistanthins A and B on blood pressure and heart rate of female Wistar rat.
Group Systolic AUC Diastolic AUC Mean AUC Heart rate AUC Systolic %
changes (mmHg)
Diastolic %
changes  (mmHg)
Mean % changes
(mmHg)
Control 5207.50 ± 255.17 3143.75 ± 247.51 3768.75 ± 200.88 12,216.25 ± 1873.08 6.04 ± 11.90 16.30 ± 20.07 11.94 ± 14.79
Cleistanthin  A 12.5 mg/kg 5318.75 ± 136.02 3907.50 ± 152.72 4330.00 ± 115.72 17,661.25 ± 673.31 −4.36 ± 6.37 (n = 5) 20.49 ± 6.43 (n = 5) 11.44 ± 6.30 (n = 5)
Cleistanthin A 25 mg/kg 5005.00 ± 170.03 3170.00 ± 151.35 3788.75 ± 158.60 9413.75 ± 2432.35 8.19 ± 3.51 17.22 ± 3.78 14.09 ± 3.19
Cleistanthin  A 50 mg/kg 4662.50 ± 115.33 2995.00 ± 201.39 3658.75 ± 89.42 13,215.00 ± 2565.74 3.06 ± 3.05 24.16 ± 5.38 15.44 ± 3.73
Cleistanthin  B 12.5 mg/kg 4396.25 ± 541.48 2632.50 ± 345.94 3308.75 ± 480.62 15,048.75 ± 2297.50 2.96 ± 8.88 15.19 ± 6.21 10.73 ± 6.60
Cleistanthin  B 25 mg/kg 4502.50 ± 195.56 2572.50 ± 334.55 3615.00 ± 144.94 16,326.25 ± 3155.61 −1.60 ± 7.56 (n = 5) 13.38 ± 4.91 (n = 5) 10.41 ± 5.95 (n = 5)
Cleistanthin B 50 mg/kg 5280.00 ± 553.22 3055.00 ± 648.48 4106.25 ± 479.33 17,698.75 ± 2494.93 9.88 ± 10.3 (n = 5) 22.77 ± 12.15 (n = 5) 17.80 ± 11.67 (n = 5)
The values are mean ± SEM; n = 6 in each group. The % change was calculated using pre-study values and 90th day values. One-way ANOVA followed by Bonferroni test. No group showed signiﬁcant differences.
Table 3
Effect of cleistanthins A and B on biochemical parameters of male Wistar rats.
Urea (mg/dL) Creatinine  (mg/dL)
Pre-study 1st month 2nd month 3rd month Pre-study 1st month 2nd month 3rd month
Control 29.50 ± 1.45 20.67 ± 1.17** 28.33 ± 0.76 21.17 ± 0.79** 0.78 ± 0.02 0.72 ± 0.02 0.72 ± 0.02 0.63 ± 0.02***
Cleistanthin  A 12.5 mg/kg 23.67 ± 2.38 23.17 ± 1.25 32.00 ± 0.87* 21.00 ± 2.48 0.75 ± 0.03 0.70 ± 0.00 0.70 ± 0.00 0.63 ± 0.02**
Cleistanthin  A 25 mg/kg 29.67 ± 3.70 20.20 ± 1.20 (n = 5)* 27.00 ± 0.58 (n = 5) 22.40 ± 0.74 (n = 5)* 0.70 ± 0.07 0.72 ± 0.02 (n = 5) 0.70 ± 0.00 (n = 5) 0.64 ± 0.02 (n = 5)*
Cleistanthin A 50 mg/kg 27.60 ± 1.18 29.00 ± 0.90 30.50 ± 1.43 22.83 ± 0.48 0.66 ± 0.11 0.80 ± 0.00* 0.72 ± 0.02* 0.63 ± 0.02*
Cleistanthin  B 12.5 mg/kg 31.50 ± 3.02 22.00 ± 0.82 27.20 ± 1.02 24.60 ± 1.21 (n = 5) 0.78 ± 0.02 0.70 ± 0.00 0.70 ± 0.00 0.62 ± 0.02 (n = 5)***
Cleistanthin B 25 mg/kg 31.00 ± 2.73 22.20 ± 1.27** 31.00 ± 0.82 35.20 ± 1.72 (n = 5)* 0.77 ± 0.02 0.70 ± 0.00 0.70 ± 0.00 0.68 ± 0.02 (n = 5)***
Cleistanthin B 50 mg/kg 31.00 ± 1.73 21.67 ± 1.78 33.17 ± 0.70* 41.00 ± 1.89 (n = 5)* 0.80 ± 0.00 0.70 ± 0.000 0.70 ± 0.00 0.620 ± 0.02 (n = 5)**
AST  (IU/L) ALT  (IU/L)
Pre-study 1st month 2nd month 3rd month Pre-study 1st month 2nd month 3rd month
Control 122.17 ± 3.53 132.80  ± 2.60 122.33  ± 10.79 121.00 ± 2.96 55.67 ± 4.32 38.60 ± 3.25 35.50 ± 2.93 48.33 ± 1.50
Cleistanthin  A 12.5 mg/kg 114.17 ± 3.30 124.00 ± 4.44 118.80 ± 2.22 147.33 ± 4.78* 49.83 ± 3.29 40.67 ± 2.04 41.00 ± 1.08 50.00 ± 3.04
Cleistanthin  A 25 mg/kg 112.00 ± 2.40 125.80 ± 7.31 (n = 5) 115.20 ± 3.70 (n = 5) 174.60 ± 6.40 (n = 5) * 51.17 ± 5.70 34.60 ± 1.21 (n = 5) 36.40 ± 1.75 (n = 5)* 50.60 ± 3.16 (n = 5)
Cleistanthin A 50 mg/kg 116.40 ± 5.09 189.83 ± 15.42* 119.83 ± 4.63 158.17 ± 2.54* 46.20 ± 3.13 37.80 ± 3.06 35.17 ± 2.46 43.00 ± 1.39
Cleistanthin  B 12.5 mg/kg 118.00 ± 4.16 125.40 ± 8.13 99.20 ± 13.46 150.60 ± 3.58 (n = 5) 64.67 ± 4.63 38.60 ± 2.91 26.60 ± 5.27 40.20 ± 1.06 (n = 5)
Cleistanthin B 25 mg/kg 111.00 ± 3.51 134.40 ± 6.50 159.00 ± 3.18 189.80 ± 22.00 (n = 5) 57.67 ± 3.29 34.40 ± 2.21 34.60 ± 1.75 47.20 ± 9.06 (n = 5)
Cleistanthin B 50 mg/kg 113.17 ± 4.87 140.33 ± 5.02 169.67 ± 18.06 169.20 ± 5.88 (n = 5) 50.67 ± 2.92 39.67 ± 2.32 36.50 ± 1.59 38.00 ± 1.66 (n = 5)
The values are mean ± SEM; n = 6 in each group; *P < 0.05, **P < 0.01 compared to pre-study (ﬁxed variable). Two-way repeated measures ANOVA followed by Bonferroni test.
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Table 4
Effect  of cleistanthins A and B on biochemical parameters of male Wistar rats.
Total protein (g/dL) Albumin (g/dL)
Pre-study 1st month 2nd month 3rd month Pre-study 1st month 2nd month 3rd month
Control 6.53 ± 0.10 6.72 ± 0.15* 6.95 ± 0.08** 7.15 ± 0.08** 3.80 ± 0.07 3.86 ± 0.02 3.82 ± 0.05 3.82 ± 0.03
Cleistanthin  A 12.5 mg/kg 6.58 ± 0.60 6.85 ± 0.11 7.08 ± 0.08 7.22 ± 0.16 3.40 ± 0.24 3.87 ± 0.09 3.82 ± 0.08 3.85 ± 0.04
Cleistanthin  A 25 mg/kg 5.12 ± 0.19 6.64 ± 0.11 (n = 5) 6.94 ± 0.10 (n = 5) 6.88 ± 0.07 (n = 5) 3.35 ± 0.08 3.86 ± 0.05 (n = 5) 3.88 ± 0.05 (n = 5) 3.82 ± 0.03 (n = 5)
Cleistanthin A 50 mg/kg 7.08 ± 0.55 7.68 ± 0.08 7.12 ± 0.13 7.350 ± 0.11 3.58 ± 0.20 4.48 ± 0.06* 3.68 ± 0.12 3.73 ± 0.10
Cleistanthin  B 12.5 mg/kg 6.72 ± 0.18 6.72 ± 0.14 6.02 ± 0.97 7.180 ± 0.15 (n = 5) 3.78 ± 0.14 3.88 ± 0.05 3.44 ± 0.49 3.92 ± 0.04 (n = 5)
Cleistanthin B 25 mg/kg 6.50 ± 0.23 6.72 ± 0.20* 7.28 ± 0.11* 7.96 ± 0.19 (n = 5)* 3.65 ± 0.07 3.84 ± 0.08* 3.96 ± 0.05* 4.12 ± 0.09* (n = 5)
Cleistanthin B 50 mg/kg 6.82 ± 0.12 6.78 ± 0.10 7.37 ± 0.12 7.90 ± 0.05 (n = 5) 3.90 ± 0.04 3.93 ± 0.07 3.93 ± 0.11 4.14 ± 0.11* (n = 5)
CKMB (IU/L)
Pre-study 1st month 2nd month 3rd month
Control 30.67 ± 4.14 42.00 ± 5.09 20.33 ± 4.77 13.17 ± 1.25
Cleistanthin  A 12.5 mg/kg 29.17 ± 5.67 21.50 ± 2.70 12.60 ± 1.60 10.83 ± 1.14
Cleistanthin  A 25 mg/kg 30.67 ± 6.40 26.20 ± 3.92 (n = 5) 17.40 ± 3.20 (n = 5) 21.60 ± 5.47 (n = 5)
Cleistanthin  A 50 mg/kg 31.20 ± 6.13 38.20 ± 9.74 13.67 ± 3.53 13.33 ± 2.08
Cleistanthin  B 12.5 mg/kg 29.00 ± 4.07 23.40 ± 2.13 13.80 ± 2.62 13.40 ± 1.34 (n = 5)
Cleistanthin  B 25 mg/kg 31.00 ± 4.03 24.80 ± 2.19 18.00 ± 4.02 52.60 ± 13.72 (n = 5)
Cleistanthin  B 50 mg/kg 29.83 ± 4.42 24.33 ± 3.60 12.50 ± 0.76 80.40 ± 23.88* (n = 5)
The values are mean ± SEM; n = 6 in each group; *P < 0.05, **P < 0.01, compared to pre-study (ﬁxed variable). Two-way repeated measures ANOVA followed by Bonferroni test.
Table 5
Effect of cleistanthins A and B on biochemical parameters of female Wistar rats.
Urea (mg/dL) Creatinine  (mg/dL)
Pre-study 1st month 2nd month 3rd month Pre-study 1st month 2nd month 3rd month
Control 26.33 ± 2.14 27.83 ± 2.41 33.33 ± 1.86 31.67 ± 1.20 0.60 ± 0.00 0.83 ± 0.03 0.77 ± 0.02 0.70 ± 0.00
Cleistanthin  A 12.5 mg/kg 30.50 ± 1.18 24.67 ± 1.69 37.33 ± 1.73 39.50 ± 1.31 0.82 ± 0.02 0.82 ± 0.02 0.75 ± 0.02* 0.73 ± 0.02*
Cleistanthin  A 25 mg/kg 25.17 ± 0.48 29.00 ± 0.90** 31.83 ± 0.87** 39.83 ± 4.11* 0.80 ± 0.00 0.80 ± 0.00 0.74 ± 0.02* 0.67 ± 0.03*
Cleistanthin  A 50 mg/kg 23.00 ± 2.46 28.67 ± 1.23* 39.00 ± 2.03* 39.00 ± 2.78* 0.55 ± 0.10 0.80 ± 0.00 0.74 ± 0.02* 0.65 ± 0.03*
Cleistanthin  B 12.5 mg/kg 26.00 ± 1.63 26.17 ± 1.74 29.00 ± 1.29 31.40 ± 1.40 (n = 5) 0.63 ± 0.02 0.78 ± 0.02*** 0.80 ± 0.03*** 0.78 ± 0.02*** (n = 5)
Cleistanthin B 25 mg/kg 26.33 ± 3.16 28.33 ± 2.01 40.00 ± 10.02 31.33 ± 1.61 0.62 ± 0.02 0.80 ± 0.00 0.93 ± 0.13 0.78 ± 0.02
Cleistanthin  B 50 mg/kg 28.00 ± 2.40 20.17 ± 1.49 30.25 ± 1.35 (n = 5) 34.67 ± 1.84 (n = 3) 0.60 ± 0.00 0.82 ± 0.02* 0.82 ± 0.02* (n = 5) 0.80 ± 0.00 (n = 3)
AST (IU/L) ALT  (IU/L)
Pre-study 1st month 2nd month 3rd month Pre-study 1st month 2nd month 3rd month
Control 116.83 ± 4.19 120.50 ± 6.23 128.00 ± 6.29 110.33 ± 4.48 49.17 ± 8.29 37.83 ± 1.85 26.67 ± 1.45 33.83 ± 1.94
Cleistanthin  A 12.5 mg/kg 114.00 ± 3.47 167.17 ± 15.48* 158.67 ± 13.76* 152.83 ± 1.54* 55.50 ± 3.60 49.25 ± 7.48* 36.33 ± 7.45* 34.17 ± 1.74*
Cleistanthin  A 25 mg/kg 112.33 ± 3.81 189.83 ± 15.42** 144.60 ± 3.50* 161.00 ± 5.82* 50.67 ± 2.87 37.80 ± 3.06 35.20 ± 3.36 39.67 ± 4.26
Cleistanthin  A 50 mg/kg 117.83 ± 2.65 168.33 ± 11.24* 137.20 ± 7.06 157.67 ± 5.67* 49.33 ± 4.15 40.33 ± 1.78* 35.00 ± 2.58* 37.83 ± 3.21*
Cleistanthin  B 12.5 mg/kg 123.20 ± 10.78 125.50 ± 6.52 135.00 ± 4.39 116.40 ± 4.81 (n = 5) 49.20 ± 8.83 43.17 ± 4.06 27.33 ± 0.96 35.20 ± 1.34 (n = 5
Cleistanthin B 25 mg/kg 110.50 ± 3.22 246.17 ± 72.76** 147.00 ± 3.06 122.50 ± 4.09 39.33 ± 3.51 163.83 ± 82.82 29.33 ± 2.68 36.33 ± 1.02
Cleistanthin  B 50 mg/kg 113.00 ± 3.44 127.17 ± 6.88 171.75 ± 11.40 (n = 5)* 122.33 ± 6.61 (n = 3) 40.60 ± 3.04 38.50 ± 2.26 39.00 ± 2.06 (n = 5) 35.00 ± 2.04 (n = 3)
The values are mean ± SEM; n = 6 in each group; *P < 0.05, **P < 0.01, ***P < 0.001 compared to pre-study values (ﬁxed variable). Two-way repeated measures ANOVA followed by Bonferroni test.
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Table 6
Effect  of cleistanthins A and B on biochemical parameters of female Wistar rats.
Total protein (g/dL) Albumin (g/dL)
Pre-study 1st month 2nd month 3rd month Pre-study 1st month 2nd month 3rd month
Control 5.60 ± 0.13 7.78  ± 0.11 7.37  ± 0.08 7.02 ± 0.08 3.57 ± 0.08 4.18 ± 0.08* 4.08 ± 0.15** 3.67 ± 0.21*
Cleistanthin  A 12.5 mg/kg 7.17  ± 0.22 8.16  ± 0.18* 8.07  ± 0.20* 8.45  ± 0.18 4.12  ± 0.07 4.42  ± 0.09* 4.27  ± 0.17 4.45  ± 0.07
Cleistanthin  A 25 mg/kg 6.97 ± 0.12 7.68 ± 0.08 7.80 ± 0.21 8.17 ± 0.11 4.20 ± 0.07 4.48 ± 0.07 4.20 ± 0.25** 4.48 ± 0.10*
Cleistanthin  A 50 mg/kg 7.35  ± 0.320 7.97  ± 0.18* 7.98  ± 0.06 8.00  ± 0.12 3.75  ± 0.13 4.57  ± 0.11* 4.54  ± 0.11* (n = 5) 4.47 ± 0.13* (n = 5)
Cleistanthin B 12.5 mg/kg 6.02 ± 0.04 7.32 ± 0.12 7.50 ± 0.20 7.46 ± 0.18 (n = 5) 3.68 ± 0.05 4.05 ± 0.08** 4.18 ± 0.09** 3.98 ± 0.11** (n = 5)
Cleistanthin B 25 mg/kg 6.17  ± 0.14 7.18  ± 0.20 7.68  ± 0.29 7.73  ± 0.19 3.78  ± 0.10 4.07  ± 0.10*** 4.18  ± 0.07*** 4.00 ± 0.08***
Cleistanthin  B 50 mg/kg 6.04  ± 0.05 6.97  ± 0.12 7.55  ± 0.12 (n = 5) 7.77 ± 0.12 (n = 3) 3.60 ± 0.06 3.80  ± 0.08 4.32  ± 0.10 (n = 5) 4.03 ± 0.09 (n = 3)
CKMB  (IU/L)
Pre-study 1st month 2nd month 3rd month
Control 34.00 ± 5.09 12.17 ± 1.17 15.50 ± 3.48 23.33 ± 4.97
Cleistanthin  A 12.5 mg/kg 28.67 ± 3.88 37.75 ± 4.81 12.67 ± 0.99 33.83 ± 4.75
Cleistanthin  A 25 mg/kg 27.50 ± 3.47 36.60 ± 4.08 13.40 ± 1.93 45.50 ± 10.81
Cleistanthin  A 50 mg/kg 31.33 ± 4.99 38.00 ± 5.01 14.00 ± 0.82 65.17 ± 23.30
Cleistanthin  B 12.5 mg/kg 29.50 ± 3.91 17.67 ± 2.17 12.83 ± 3.049 139.60 ± 31.19* (n = 5)
Cleistanthin  B 25 mg/kg 31.17 ± 4.39 31.50 ± 9.88 10.67 ± 2.94 74.17 ± 11.97
Cleistanthin  B 50 mg/kg 27.60 ± 6.03 16.17 ± 3.06 8.50 ± 1.27 (n = 5) 76.67 ± 23.14 (n = 3)
The values are mean ± SEM; n = 6 in each group; *P < 0.05, **P < 0.01, ***P < 0.001 compared to pre-study values (ﬁxed variable). Two-way repeated measures ANOVA followed by Bonferroni test.
Table 7
Effect  of cleistanthin A on mortality of rat.
Drug and dose Number of animals died Description
M (n = 6) F  (n = 6)
Control (0.5% CMC) 0 0
Cleistanthin A 12.5 mg/kg 0 0
Cleistanthin A 25 mg/kg 1  0 Male rate died on 14th day
Cleistanthin  A 50 mg/kg 0 0
Cleistanthin A 100 mg/kg 2 2 Male rats died on 28th and 30th day and female rats died on 25th and 30th day
Cleistanthin  A 200 mg/kg 2 2 Male rats died on 10th and 12th day and female rats died on 7th and 14th day
Cleistanthin  A 400 mg/kg 2 3 Male rats died on 4th and 6th day and female rats died on 4th, 5th and 6th day
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Table 8
Effect of cleistanthin B on mortality of rat.
Drug and dose Number of animals died Description
M (n = 6) F (n = 6)
Control (0.5% CMC) 0 0
Cleistanthin B 12.5 mg/kg 1 1 Male rats died on 70th day and female animal died on 65th day
Cleistanthin B 25 mg/kg 1 0 Male rats died on 82nd day
Cleistanthin B 50 mg/kg 1 3 Male rats died on 80th and female rats died on 52nd, 67th and 72nd day of drug administration
Cleistanthin  B 100 mg/kg 2 3 Male rats died on 18th and 25th day of and female rats died on 17th, 23rd and 31th day
Cleistanthin B 200 mg/kg 3 3 Male rats died on 5rd and 9th (2 Nos.) day and female rats died on 4th (2 Nos.) and 7th day
Cleistanthin B 400 mg/kg 5 4 Male rats died on 3rd, 4th (2 Nos.) and 5th (2 Nos.) day and female rats died on 2nd (2 Nos.) and 3rd (2 Nos.) day
Table 9
Histopathological summary report of cleistanthin A.
Treatment Organ Male Female
Control Normal Normal
Cleistanthin A 12.5 mg/kg
Brain  Normal ↑ Corpora amylacea
Lung Interstitial pneumonitis Severe interstitial pneumonitis
Heart Normal Normal
Liver  Normal Normal
Stomach Normal Normal
Kidney Normal Acute  tubular necrosis
Bone marrow Normal Normal
Cleistanthin A 25 mg/kg
Brain  ↑ Corpora amylacea ↑ Corpora amylacea
Lung Inﬂammation in lung; Interstitial pneumonitis (↑↑) and collapse of alveolar air
spaces
Severe  interstitial pneumonitis
Heart Normal Normal
Liver  Normal Normal
Stomach Normal Normal
Kidney Normal Acute  tubular necrosis
Bone marrow Normal Normal
Cleistanthin A 50 mg/kg
Brain  ↑ Corpora amylacea ↑ Corpora amylacea
Lung Severe interstitial pneumonitis, crystalline deposition and foreign body giant
cell
Severe  interstitial pneumonitis, crystalline deposition and
foreign body  giant cell reaction
Heart Normal Normal
Liver  Normal Normal
Stomach Normal Normal
Kidney Normal Acute  tubular necrosis
Bone marrow Normal Normal
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Table 10
Histopathological summary report of cleistanthin B.
Treatment Organ Male Female
Control Normal Normal
Cleistanthin B 12.5 mg/kg
Brain  ↑ Corpora amylacea Normal
Lung Mild interstitial pneumonitis Interstitial pneumonitis and severe focal necrosis
Heart Normal Normal
Liver Normal Spotty necrosis
Stomach Normal Normal
Kidney Normal Acute tubular  necrosis
Bone marrow Normal Normal
Cleistanthin B 25 mg/kg
Brain  ↑ Corpora amylacea ↑ Corpora amylacea
Lung Severe interstitial pneumonitis with dense inﬁltration of neutrophils, eosinophils
and  foamy macrophages with collapse of alveolar space
Lung-severe interstitial pneumonitis; collection of macrophages,
pulmonary oedema and extensive destruction
Heart Normal Normal
Liver Normal Normal
Stomach Normal Normal
Kidney Normal Acute tubular  necrosis
Bone marrow Normal Normal
Cleistanthin B 50 mg/kg
Brain  ↑ Corpora amylacea ↑ Corpora amylacea
Lung Extensive destruction of lung parenchyma, severe interstitial pneumonitis Crystalline deposition, severe interstitial pneumonitis, extensive necrosis,
pulmonary haemorrhage
Heart Myocardial infarction Normal
Liver Spotty necrosis Spotty necrosis
Stomach Normal Normal
Kidney Acute tubular necrosis Acute tubular  necrosis
Bone marrow Normal Normal
Table 11
Effect of cleistanthins A and B on DNA toxicity.
Group Number of DNA analysed Comet length (m) Head diameter (m) %DNA in head Tail length (m) %DNA in tail
Control 152 23.37 ± 0.40 23.18 ± 0.36 97.69 ± 0.24 1.14 ± 0.18 2.31 ± 0.24
Cle  A 25 mg/kg 152 32.10 ± 1.28** 24.12 ± 0.41 92.07 ± 0.76*** 8.35 ± 1.02* 7.93 ± 0.76***
Cle  A 50 mg/kg 180 63.55 ± 2.54*** 28.18 ± 0.41*** 79.82 ± 0.89*** 35.46 ± 2.27*** 20.18 ± 0.89***
Cle  A 25 mg/kg 150 37.94 ± 0.68*** 26.14 ± 0.42*** 87.89 ± 0.56*** 11.80 ± 0.60*** 12.11 ± 0.56***
Cle  B 50 mg/kg 158 76.34 ± 2.21*** 32.83 ± 0.51*** 78.89 ± 0.80*** 43.50 ± 2.00*** 21.11 ± 0.80***
All the values are mean ± SEM; n = 3 animals; *P < 0.05, **P < 0.01, ***P < 0.001 compared to control. One-way ANOVA followed by Bonferroni test.
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Table 12
Effect  of cleistanthins A and B on absolute organ weight of male Wistar rats (g).
Group Brain Heart Lung Stomach Liver Kidney (L) Kidney (R) Mean kidney wt.  Testis (L) Testis (R) Mean testis wt.
Control 1.85 ± 0.14 0.69 ± 0.03 1.58 ± 0.09 2.00 ± 0.11 7.48 ± 0.58 0.88 ± 0.05 0.80 ± 0.04 0.84 ± 0.05 2.30 ± 0.19 2.01 ± 0.22 2.15 ± 0.20
Cleistanthin  A
12.5  mg/kg
1.96  ± 0.09 0.80  ± 0.07 1.45  ± 0.17 2.23  ± 0.14 8.74 ± 0.99 1.03 ± 0.07 0.97 ± 0.06** 1.00 ± 0.07* 2.76 ± 0.20 2.59 ± 0.25 2.67 ± 0.23
Cleistanthin  A
25  mg/kg
1.94  ± 0.07 0.77  ± 0.01 1.57 ± 0.09 2.14 ± 0.14 8.53 ± 0.70 0.92 ± 0.03 0.91 ± 0.04 0.92 ± 0.03 2.55 ± 0.21 2.64 ± 0.25 2.60 ± 0.23
Cleistanthin  A
50  mg/kg
1.87  ± 0.07 0.83 ± 0.06 1.65 ± 0.11 2.05 ± 0.16 8.02 ± 0.92 0.99 ± 0.07 0.94 ± 0.10* 0.97 ± 0.08 2.63 ± 0.08 2.43 ± 0.11 2.53 ± 0.09
Cleistanthin  B
12.5  mg/kg
1.87  ± 0.13 0.85 ± 0.05 2.00 ± 0.18*** 1.92 ± 0.17 8.67 ± 0.61 1.12 ± 0.11*** 1.06 ± 0.10*** 1.09 ± 0.10*** 2.97 ± 0.31 2.88 ± 0.30 2.92 ± 0.30
Cleistanthin  B
25  mg/kg
1.92  ± 0.05 0.83  ± 0.05 1.64  ± 0.13 1.94  ± 0.10 8.97  ± 0.33* 1.13  ± 0.09*** 1.04  ± 0.09*** 1.08  ± 0.09*** 2.53 ± 0.18 2.43  ± 0.19 2.48  ± 0.18
Cleistanthin  B
50  mg/kg
2.10  ± 0.10* 0.78 ± 0.07 1.83 ± 0.10* 1.88 ± 0.08 9.28 ± 0.77** 1.17 ± 0.11*** 1.00 ± 0.06*** 1.09 ± 0.08*** 2.60 ± 0.06 2.57 ± 0.13 2.58 ± 0.09
The values are mean ± SEM; n = 6 in each group; *P < 0.05, **P < 0.01, ***P < 0.001, compared to control. One-way ANOVA followed by Bonferroni test.
Table 13
Effect of cleistanthins A and B on relative organ weight of male Wistar rats (g).
Group Brain Heart Lung Stomach Liver Kidney (L) Kidney (R) Avg. kidney wt.  Testis (L) Testis (R) Mean. Testis wt.
Control 0.85 ± 0.04 0.32 ± 0.02 0.74 ± 0.05 0.92 ± 0.02 3.46 ± 0.25 0.41 ± 0.03 0.37 ± 0.02 0.39 ± 0.02 1.07 ± 0.10 0.93 ± 0.10 1.00 ± 0.10
Cleistanthin  A
12.5  mg/kg
0.85 ± 0.07 0.34 ± 0.02 0.62 ± 0.06* 0.96 ± 0.06 3.68 ± 0.27 0.44 ± 0.03 0.41 ± 0.02 0.42 ± 0.02 1.18 ± 0.09 1.12 ± 0.12* 1.15 ± 0.10
Cleistanthin  A
25  mg/kg
0.84 ± 0.040 0.33 ± 0.01 0.67 ± 0.01 0.91 ± 0.03 3.64 ± 0.22 0.40 ± 0.01 0.39 ± 0.02 0.39 ± 0.01 1.09 ± 0.06 1.12 ± 0.06* 1.10 ± 0.06
Cleistanthin  A
50  mg/kg
0.89 ± 0.06 0.40 ± 0.03*** 0.78 ± 0.05 0.98 ± 0.11 3.75 ± 0.37 0.47 ± 0.04 0.44 ± 0.04* 0.46 ± 0.04 1.24 ± 0.06 1.15 ± 0.07* 1.20 ± 0.06*
Cleistanthin  B
12.5  mg/kg
0.92 ± 0.07 0.42 ± 0.02*** 0.98 ± 0.09*** 0.94 ± 0.08 4.25 ± 0.34** 0.55 ± 0.06*** 0.52 ± 0.05*** 0.53 ± 0.05*** 1.47 ± 0.18*** 1.42 ± 0.16*** 1.44 ± 0.17***
Cleistanthin  B
25  mg/kg
0.90 ± 0.04 0.39 ± 0.03*** 0.77 ± 0.08 0.91 ± 0.06 4.20 ± 0.21** 0.53 ± 0.05*** 0.49 ± 0.05*** 0.509 ± 0.05*** 1.18 ± 0.09 1.14 ± 0.09* 1.16 ± 0.09
Cleistanthin  B
50  mg/kg
1.07 ± 0.04*** 0.38 ± 0.01* 0.94 ± 0.05*** 0.96 ± 0.02 4.71 ± 0.45*** 0.60 ± 0.06*** 0.51 ± 0.03*** 0.55 ± 0.04*** 1.36 ± 0.07 1.27 ± 0.05*** 1.31 ± 0.06***
The values are mean ± SEM; n = 6 in each group; *P < 0.05, **P < 0.01, ***P < 0.001, compared to control. One-way ANOVA followed by Bonferroni test.
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Table 14
Effect of cleistanthins A and B on absolute organ weight of female Wistar rats (g).
Group Brain Heart Lung Stomach Liver Kidney (L) Kidney (R) Mean kidney wt.  Uterus
Control 1.88 ± 0.06 0.59 ± 0.04 1.63 ± 0.06 1.43 ± 0.13 6.06 ± 0.32 0.70 ± 0.03 0.66  ± 0.03 0.68 ± 0.03 3.62  ± 0.35
Cleistanthin  A 12.5 mg/kg 1.90 ± 0.24 0.65 ± 0.06 1.70 ± 0.16 1.87 ± 0.25*** 6.45 ± 0.56 1.10 ± 0.17*** 0.92 ± 0.14*** 1.01 ± 0.15*** 2.96 ± 0.30*
Cleistanthin  A 25 mg/kg 1.66 ± 0.14 0.59 ± 0.04 1.63 ± 0.14 1.56 ± 0.06 6.42 ± 0.27 0.80 ± 0.03 0.75 ± 0.02 0.78 ± 0.03 3.47 ± 0.38
Cleistanthin  A 50 mg/kg 1.98 ± 0.06 0.63 ± 0.05 1.59 ± 0.11 1.48 ± 0.131 6.13 ± 0.32 0.85 ± 0.04 0.74 ± 0.03 0.79 ± 0.03 2.86 ± 0.30**
Cleistanthin  B 12.5 mg/kg 2.38 ± 0.05*** 0.72 ± 0.05** 1.89 ± 0.03** 1.86 ± 0.07*** 6.70 ± 0.63 0.93 ± 0.04** 0.90 ± 0.05*** 0.92 ± 0.05*** 3.24 ± 0.29
Cleistanthin  B 25 mg/kg 2.31 ± 0.12*** 0.62 ± 0.03 1.89 ± 0.08** 1.76 ± 0.10** 7.37 ± 0.06*** 1.11 ± 0.18*** 0.90 ± 0.04*** 1.00 ± 0.11*** 3.78 ± 0.30
Cleistanthin  B 50 mg/kg 2.20 ± 0.08** 0.69 ± 0.09 1.85 ± 0.02** 1.99 ± 0.08*** 6.25 ± 0.14 0.97 ± 0.05*** 0.91 ± 0.04*** 0.94 ± 0.05*** 3.55 ± 0.45
The values are mean ± SEM; n = 6 in each group; *P < 0.05, **P < 0.01, ***P < 0.001, compared to control. One-way ANOVA followed by Bonferroni test.
Table 15
Effect of cleistanthins A and B on relative organ weight of female Wistar rats (g).
Group Brain Heart Lung Stomach Liver Kidney (L) Kidney (R) Avg. kidney wt. Uterus
Control 1.25 ± 0.03 0.39 ± 0.03 1.09 ± 0.04 0.95 ± 0.08 4.04 ± 0.20 0.47 ± 0.01 0.44 ± 0.01 0.45 ± 0.01 2.42 ± 0.23
Cleistanthin  A 12.5 mg/kg 1.17 ± 0.13 0.40 ± 0.02 1.05 ± 0.08 1.14 ± 0.13* 4.01 ± 0.27 0.70 ± 0.14*** 0.58 ± 0.11*** 0.64 ± 0.12*** 1.85 ± 0.19***
Cleistanthin  A 25 mg/kg 1.13 ± 0.12 0.39 ± 0.02 1.09 ± 0.07 1.05 ± 0.04 4.31 ± 0.15 0.54 ± 0.01 0.50 ± 0.01 0.52 ± 0.01 2.31 ± 0.20
Cleistanthin  A 50 mg/kg 1.36 ± 0.10 0.43 ± 0.04 1.10 ± 0.12 0.83 ± 0.18 4.15 ± 0.22 0.58 ± 0.04 0.50 ± 0.03 0.54 ± 0.04 1.96 ± 0.27**
Cleistanthin  B 12.5 mg/kg 1.54 ± 0.03** 0.48 ± 0.03** 1.20 ± 0.02 1.18 ± 0.05** 4.22 ± 0.41 0.59 ± 0.03 0.58 ± 0.03*** 0.58 ± 0.03** 1.90 ± 0.14**
Cleistanthin  B 25 mg/kg 1.45 ± 0.08* 0.39 ± 0.01 1.20 ± 0.08 1.11 ± 0.08 4.65 ± 0.18** 0.69 ± 0.11*** 0.56 ± 0.02** 0.63 ± 0.07*** 2.38 ± 0.20
Cleistanthin  B 50 mg/kg 1.31 ± 0.09 0.41 ± 0.06 1.11 ± 0.07 1.18 ± 0.06** 3.73 ± 0.21 0.57 ± 0.03 0.54 ± 0.03* 0.56 ± 0.03 2.05 ± 0.09
The values are mean ± SEM; n = 6 in each group; *P < 0.05, **P < 0.01, ***P < 0.001, compared to control. One-way ANOVA followed by Bonferroni test.
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Fig. 3. (a) Section from brain of cleistanthin A (25 mg/kg) treated ani- Fig. 4. (a) Section from kidney of cleistanthin A (25 mg/kg) treated ani-
rise  but it appears the body gets adapted to cleistanthins
by about 3 months. This explains the full or partial return
from  raised levels of parameters. In case of creatinine, itmal  shows increased corpora amylacea in cerebral cortex, H&E, 100×. (b)
Section from brain of cleistanthin B (12.5 mg/kg) treated animal shows
increased corpora amylacea (arrow) in cerebral cortex, H&E, 400×.
testis when the dose was raised to 25 mg/kg in male ani-
mals  when compared to control. While cleistanthin A at
50  mg/kg increased the relative organ weights of heart, kid-
ney  and testis (P < 0.05), cleistanthin B at 25 mg/kg raised
the  relative organ weight of heart, lung, liver, kidney and
testis  but only in male animals (P < 0.01). Effect of cleis-
tanthins A and B on absolute and relative organ weight is
shown  in Tables 12–15.
Cleistanthin  B from 12.5 mg/kg onwards showed a sig-
niﬁcant increase in the absolute organ weight of heart,
lung, liver, brain, stomach, kidney and uterus in female rats.
When  compared to cleistanthin A, cleistanthin B signiﬁ-
cantly increased the absolute and relative organ weight of
the  heart, lung and liver in female rats. We  have no explana-
tion  as to why the weight of the organs changes other than
that  it could be due to some defence mechanism of the body
to  tackle the continuous presence of a poisonous substance.
Such  attribution draws some support from the histopatho-
logical data presented here. While the histopathologically
affected organs such as heart, lung, liver and kidney showed
signiﬁcant weight changes, those organs such as stomach
and  testes did not show any change either in histopatho-
logy or weight.
The  baseline (pre-study) values of biochemical param-
eters are within the normal range in all the experimental
animals. Cleistanthins A and B signiﬁcantly altered the fas-
ting  blood glucose, urea, creatinine, ALT, ALP, total protein,
albumin and CKMB level in both the genders during themals shows acute tubular necrosis, H&E, 100×. (b) Section from kidney of
cleistanthin A (12.5 mg/kg) treated animal shows acute tubular necrosis
(arrow), H&E, 400×.
course of the experiment (Tables 3–6). But most of the
parameters returned close to their original levels at the end
of  the study. There is no clear cut dose dependent effect
exerted by either cleistanthin A or cleistanthin B. But cre-
atinine  levels remain raised in both the sexes even at the
end  of the study (Tables 3 and 5). The continuous pres-
ence  of cleistanthins made the biochemical parameters toFig. 5. Section from liver of cleistanthin B (50 mg/kg) treated animal
shows ground glass hepatocytes. Kupfer cell hyperplasia with increased
hemosiderin deposition (arrow), H&E, 400×.
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Fig. 6. Section from heart of cleistanthin B (50 mg/kg) treated animal
s
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(hows myocardial infarction, H&E, 400×.
s already reported that the kidney functions are affected
y  cleistanthin and hence it is no surprise that the levels
f  creatinine remain higher at the end of the study. Para-
uraman et al. studied the effect of cleistanthins A and B
n  pH, urine volume and urinary ions, and they concluded
hat both cleistanthins A and B did not alter the pH of the
rine  at acute dosing, increased the urine excretion level at
–24  h and increased the potassium ion excretion at 0–5 h
nd  5–24 h. The diuretic effect of both cleistanthins A and
 is not dose dependent [22].
ig. 7. (a) Section from lung of cleistanthin A (25 mg/kg) treated animal shows den
ection  from lung of cleistanthin A (50 mg/kg) treated animal shows acute interst
lasma  cells. There is evidence of focal retractile crystalline deposition surrounde
ung  of cleistanthin B (12.5 mg/kg) treated animal shows increased hemosiderin d
50 mg/kg) treated animal shows extensive necrosis with collapsed air space andFig. 8. Section from liver parenchyma of cleistanthin B (50 mg/kg) treated
animals shows spotty hepatic necrosis, H&E, 400×.
It is important to note even though cleistanthins A and
B  caused signiﬁcant alterations in biochemical parameters
such as glucose, creatinine, AST, ALT, ALP, albumin, urea
and  total protein, the values still remained in the normal
range. The signiﬁcant changes are due to the effect of the
investigational compounds on morphology and function of
liver  and kidney.
Histopathological ﬁndings are presented in
Tables 9 and 10. The histopathological analysis showed
dose dependent morphological changes in the lung, kid-
ney  and heart. Control group animals did not show any
se interstitial inﬁltration by lymphocytes and monocytes, H&E, 100×. (b)
itial pneumonitis with dense inﬁltration of neutrophils, lymphocytes and
d by foreign body giant cell reaction (arrow), H&E, 400×. (c) Section from
eposition, H&E, 50×. (d) Section from lung parenchyma of cleistanthin B
 marked interstitial inﬂammation, H&E, 400×.
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Fig. 9. Effects of cleistanthins A and B on genotoxicity (comet assay). (a)
Visual scoring of DNA damage from control animal, study sample: albino
Wistar rat mononuclear cells, stain: silver nitrate, magniﬁcation: ×400.
(b)  Visual scoring of DNA damage from cleistanthin A 50 mg/kg treated
animal, study sample: albino Wistar rat mononuclear cells, stain: sil-
ver nitrate, magniﬁcation: ×400. (c) Visual scoring of DNA damage from
cleistanthin B 50 mg/kg treated animal, study sample: albino Wistar rat
mononuclear cells, stain: silver nitrate, magniﬁcation: ×400.eports 1 (2014) 596–611
changes in the brain, lung, heart, liver, stomach, kidney
and bone marrow. Both the compounds produced a dose
dependent increase of corpora amylacea in brain (Fig. 3a
and  b) and induced acute tubular necrosis in kidneys
(Fig. 4a and b). In addition, cleistanthin B caused spotty
necrosis of liver at higher doses (Fig. 5). Cleistanthin B at
a  dose of 50 mg/kg and above caused infarction in cardiac
muscle (Fig. 6). Comparatively cleistanthin B had more
toxic  effect in Wistar rats. Cleistanthins A and B caused a
dose  dependent toxic effect in lungs which includes mild
to  severe interstitial pneumonitis with dense inﬁltration
by neutrophils, eosinophils and foamy macrophages,
pulmonary edema and destruction of lung parenchyma.
Cleistanthin B alone caused crystalline deposition and
pulmonary haemorrhage in lungs at the doses of 50 mg/kg
and  above (Fig. 7a–d). Both cleistanthins A and B caused
spotty necrosis and ground glass hepatocytes in liver at a
dose  higher than 50 mg/kg (Fig. 8). Histological analysis
of  heart showed the presence of myocardial infarction
in animals treated with a high dose of cleistanthin
B.
The histological ﬁnding of the bone marrow was normal
indicating that the investigational compounds do not affect
the  rapidly dividing cells. But it is interesting to note that
these  compounds cause DNA damage in mature cells like
lymphocytes. There were reports that these compounds
showed anticancer effect in vitro and it is worth explor-
ing  the anticancer effects of the compounds further since
they  do not affect the rapidly dividing normal cells [8,10].
Cleistanthin A and cleistanthin B caused signiﬁcant DNA
damage (Table 11). Both the compounds showed a signif-
icant  increase in comet length and head diameter of the
DNA.  The percentage of DNA in head portion was reduced
signiﬁcantly in cleistanthins A and B treated animals. The
visual  observation images are presented in Fig. 9. Since
cleistanthins A and B are capable of causing signiﬁcant
DNA damage, the anti-tumour activity of these compounds
deserves exploration.
Histological ﬁndings showed alterations in normal
architecture of the tissue. It is suggested that cleistanthins A
and  B exert a dose dependent toxic effect in liver and heart.
Biochemical analysis for cardiac marker such as CK-MB
showed a signiﬁcant increase within 2 months of treat-
ment. This ﬁnding was supported by histological analysis
of  heart tissue.
The  computer aided predictions for toxicity of cleistan-
thin A and cleistanthin B did not show any signiﬁcant/major
toxic effect [23]. The calculated NOEL (no observable
effect level) dose [NOEL = LD50 (mg/kg) × 70 (kg a per-
son)/Empirical constant (2000)] for cleistanthins A and B
was  42 and 35 mg/day respectively [24].
In  humans the plant was reported to induce death after
3–5  days after the consumption of leaf extract or paste
made of leaves. The cause of death in humans was either
cardiac arrest or respiratory arrest. In the present study
the  respiratory depression is evident in low doses and the
compounds also cause cardiac toxicity. This explains the
cause  of death reported in humans. The higher doses of the
compounds cause death in rodents around 5 days which is
conformity  with timeline of mortality occurring in humans
poisoned with C. collinus.
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. Conclusion
Both cleistanthins A and B exert severe toxic effects
n lungs, brain, liver, heart and kidneys. Also, they induce
enotoxicity in blood lymphocytes but have no effect on
one  marrow. We  conclude that the investigational prod-
cts  exert toxicity on multiple organs but spare the rapidly
ividing cells like stem cells and progenitor cells and this
roperty would be much desirable, if these compounds
re successfully developed into anticancer agents as they
ave  been reported to exert anticancer activity. Further the
oxicity  proﬁle presented here might be of help, if investi-
ations for the treatment of poisoning are undertaken and
lso  if the compounds themselves are investigated as lead
ompounds for therapeutic purposes in future.
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